ストックスクリーナーアプリを入手
0.7311
0.19%
-0.0014
前日終値:
$0.7325
開ける：
$0.732
24時間の取引高:
36,691
Relative Volume:
0.02
時価総額：
$4.22M
収益：
-
当期純損益:
$-16.08M
株価収益率:
-0.0212
EPS:
-34.43
ネットキャッシュフロー:
$-11.54M
1週間 パフォーマンス:
-6.39%
1か月 パフォーマンス:
-36.97%
6か月 パフォーマンス:
-48.87%
1年 パフォーマンス:
-91.50%
1日の値動き範囲:
$0.7049
$0.732
1週間の範囲:
$0.7049
$0.837
52週間の値動き範囲:
$0.5933
$9.9875
Bio Path Holdings Inc Stock (BPTH) Company Profile
名前
Bio Path Holdings Inc
セクター
電話
(832) 742-1357
住所
4710 BELLAIRE BOULEVARD, BELLAIRE, TX
BPTH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.7311 | 4.22M | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.45 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
713.93 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
669.14 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.05 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.31 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-11 | 開始されました | ROTH Capital | Buy |
| 2017-11-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-10 | 繰り返されました | Maxim Group | Buy |
| 2016-04-18 | 開始されました | Rodman & Renshaw | Buy |
| 2014-06-02 | 再開されました | Maxim Group | Buy |
| 2014-05-09 | 開始されました | Maxim Group | Buy |
すべてを表示
Bio Path Holdings Inc (BPTH) 最新ニュース
Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com - Defense World
Thyroid Cancer Drugs Market on Track of Significant Expansion by 2031 | Biovista, Vascular Biogenics, Azaya - EIN News
Bio-Path Holdings Updates Clinical Trial Data and it Sounds Promising - AccessWire
Bio-Path (BPTH) Stock Price, News & Analysis - MarketBeat
Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com - Defense World
Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode - MSN
Pre-market Movers: HSDT, PBM, MTEM, APTO... - RTTNews
Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com - Defense World
Bio-Path Holdings Advances Clinical Pipeline for 2025 - TipRanks
Bio-Path readies for key 2025 clinical milestones By Investing.com - Investing.com Australia
Bio-Path provides 2025 clinical, operational update - TipRanks
Bio-Path readies for key 2025 clinical milestones - Investing.com India
Bio-Path Holdings Provides 2025 Clinical and Operational Update - The Manila Times
Bio-Path's DNAbilize Platform Shows Promise in Cancer Trials, Expands to Diabetes Treatment - StockTitan
Evaxion announces plan to implement ADS ratio change - Seeking Alpha
Is This Penny Stock a Buy After a 180% Rally? - MSN
Is This Penny Stock A Buy After A 180% Rally? - Barchart
Bio-Path Holdings Advances Clinical Trials and Secures $4 Million in Funding - Citybuzz
Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World
NoticeTEKNOSCAN SYSTEMS INC., H. SAMUEL HYAMS, PHILIP KAI-HING KUNG and SOON FOO (MARTIN) TAM, File No. 2022-19 - Barchart
Studies of Bio-path’s BP-1001-A show potential in obesity, diabetes - BioWorld Online
Bio-Path Holdings (BPTH) Surges Over 406% Following Positive Pre - GuruFocus.com
Bio-Path Holdings: Promising Preclinical Results for BP1001-A - TipRanks
MRVI Stock Drops 5% Amidst Biotech Sector Decline - GuruFocus.com
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline - Benzinga
Bio-Path More Than Doubles on Preclinical Results of BP1001-A for Obesity - MarketWatch
Industry Leader Climet Partners with Phizzle; One of the First Joint TCO/ROI Value Proposition in Pharma Manufacturing - Newsfile
Bio-Path Holdings Shares Were On The Rise: What's Going On? - Benzinga
Gold Falls Sharply, Lamb Weston Shares Plunge - Benzinga
Innovative therapies and military tech drive early trading gains - RagingBull
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Artificial Intelligence (AI) News Live Feed - StockTitan
Wall Street-Heavily Traded - WDRB
Bio-Path (BPTH) Stock Rides High On Promising Trial Results - Stocks Telegraph
Clinical Trials News Live Feed - StockTitan
Bio-Path reports potential obesity treatment success - Investing.com
Bio-Path's Breakthrough Drug Shows Promise in Diabetes Treatment, Phase 1 Trial Set for 2025 - StockTitan
VueReal Showcases Industry-First MicroLED Design Reference Kits at CES 2025, Driving Global Innovation Across Key Industries - Newsfile
Bio-Path Holdings Faces Nasdaq Compliance and Strategic Changes - MSN
Bullfrog AI CFO Passes Away - Defense World
Rafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsNEWARK, NJ – December 11, 2024 – Rafael Holdings, Inc. (NYSE: RFL) released its financial results for the first quarter of fiscal year 2025, ended October 31, 2024. The company announ - Defense World
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients - Defense World
SouthState (NASDAQ: SSB) Receives Regulatory Approvals for Merger with Independent Bank Group - Defense World
Bio-Path Holdings faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Bio-Path Holdings faces Nasdaq delisting over share price - Investing.com
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24 - The Kingston Whig-Standard
Bio-Path Holdings Shifts Focus to Metabolic Program - TipRanks
CNB Financial Services, Inc. goes ex dividend tomorrow - MSN
VueReal Highlights Revolutionary MicroLED Solutions at CES 2025 - Newsfile
Bio-Path refocuses on diabetes drug amid trial challenges By Investing.com - Investing.com South Africa
Bio Path Holdings Inc (BPTH) 財務データ
収益
当期純利益
現金流量
EPS
0.48%
3.35%
大文字化:
|
ボリューム (24 時間):